Characterization of Platelet Lysate Cultured Mesenchymal Stromal Cells and Their Potential Use in Tissue-Engineered Osteogenic Devices for the Treatment of Bone Defects

2010 ◽  
Vol 16 (2) ◽  
pp. 201-214 ◽  
Author(s):  
Agnese Salvadè ◽  
Pamela Della Mina ◽  
Diego Gaddi ◽  
Francesca Gatto ◽  
Antonello Villa ◽  
...  
2011 ◽  
Vol 17 (2) ◽  
pp. S169
Author(s):  
G. Lucchini ◽  
E. Dander ◽  
A. Rovelli ◽  
A. Balduzzi ◽  
S. Bonanomi ◽  
...  

2013 ◽  
Vol 41 (8) ◽  
pp. S64
Author(s):  
Antonella Conforti ◽  
Marco Scarsella ◽  
Ezio Giorda ◽  
Simone Biagini ◽  
Nadia Starc ◽  
...  

Cytotherapy ◽  
2017 ◽  
Vol 19 (5) ◽  
pp. S164-S165
Author(s):  
A. Laitinen ◽  
T. Kaartinen ◽  
S. Oja ◽  
M. Korhonen ◽  
K. Alfthan ◽  
...  

Author(s):  
Katia Mareschi ◽  
Sara Castiglia ◽  
Aloe Adamini ◽  
Deborah Rustichelli ◽  
Elena Marini ◽  
...  

For their clinical use Mesenchymal Stromal Cells (MSCs), isolated from bone marrow (BM-MSCs) are considered Advanced Therapy Medicinal Products (ATMP) and need to be produced according to Good Manufacturing Practice (GMP). Human platelet lysate (HPL) represents a good GMP-compliant alternative to animal serum and after pathogen inactivation with Psoralen was more efficient and safer to produce MSCs in GMP. In this study MSCs cultivated in FBS (FBS-MSC) or inactivated HPL (iHPL-MSC), were compared for their immunomodulant properties. In particular, the effects of MSCs on: 1)proliferation of total Lymphocytes (Ly) and on naïve T Ly subsets induced to differentiate versus Th1 and Th2 Ly; 2) the immunophenotype of different T cell subsets; 3)the cytokine release to verify Th1, Th2 and Th17 polarization were analyzed by using in vitro co-culture system. We observed that iHPL-MSCs showed the same immunomodulant properties observed in the FBS-MSCs co-cultures. Although, a more efficient effect on the increase of naïve T cells and, in the Th1 cytokine release related to iHPL was observed. This study confirms that iHPL, used as medium supplement, may be considered a good alternative to FBS for a GMP-compliant MSC expansion to preserve their immunomodulant proprieties.


2013 ◽  
Vol 55 (5) ◽  
pp. 1203-1205 ◽  
Author(s):  
Lucia Silla ◽  
Vanessa Valim ◽  
Bruna Amorin ◽  
Ana Paula Alegretti ◽  
Fernanda dos Santos de Oliveira ◽  
...  

2017 ◽  
Vol 38 (11) ◽  
pp. 1511-1520 ◽  
Author(s):  
Judith Böhringer ◽  
René Santer ◽  
Neele Schumacher ◽  
Friederike Gieseke ◽  
Kerstin Cornils ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document